ciltacabtagene autoleucel sold brand name carvykti anticancer medication used treat multiple ciltacabtagene autoleucel bcma bcell maturation antigendirected genetically modified autologous chimeric antigen receptor car tcell dose customized using recipients tcells collected genetically modified infused back common adverse reactions include pyrexia cytokine release syndrome hypogammaglobulinemia musculoskeletal pain fatigue infections diarrhea nausea encephalopathy headache coagulopathy constipation additional common side effects include neutropenia low levels neutrophils lymphopenia leucopenia low levels lymphocytes white blood cells anemia low levels red blood cells thrombocytopenia low levels blood platelets hypotension low blood pressure pain muscles bones high level liver enzymes upper respiratory tract infection nose throat infection diarrhea hypokalemia low level potassium hypocalcemia low levels calcium hypophosphatemia low levels phosphate blood nausea headache cough tachycardia rapid heartbeat encephalopathy brain disorder edema fluid retention decreased appetite chills fever tiredness well cytokine release syndrome potentially lifethreatening condition cause fever vomiting shortness breath pain low blood ciltacabtagene autoleucel approved medical use united states february european union may us ciltacabtagene autoleucel indicated treatment adults relapsed refractory multiple myeloma four prior lines therapy including proteasome inhibitor immunomodulatory agent monoclonal eu indicated treatment adults relapsed refractory multiple myeloma received least three prior therapies including immunomodulatory agent proteasome inhibitor antibody demonstrated disease progression last safety efficacy ciltacabtagene autoleucel evaluated open label multicenter clinical trial evaluating ciltacabtagene autoleucel participants relapsed refractory multiple myeloma received least three prior lines therapy included proteasome inhibitor immunomodulatory agent monoclonal antibody disease progression last chemotherapy regimen received four prior lines antimyeloma us food drug administration fda granted application ciltacabtagene autoleucel priority review breakthrough therapy orphan drug march committee medicinal products human use chmp european medicines agency ema adopted positive opinion recommending granting conditional marketing authorization medicinal product carvykti intended treatment adults relapsed refractory multiple applicant medicinal product janssencilag international ciltacabtagene autoleucel approved medical use european union may httpsenwikipediaorgwikiciltacabtageneautoleucel